SCHEMBL6433843

SCHEMBL6433843

CC(C)(C)OC(=O)CCNC(=O)c1ccc2c(N(Cl)C(=N)N)cncc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.41
CSNK2A2 P19784 2/20 0.36
CSNK2B P67870 2/20 0.36
CSNK2A1 P68400 2/20 0.36
CSNK2A3 Q8NEV1 2/20 0.36
CLK2 P49760 1/20 0.36
PTPRC P08575 2/20 0.34
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NAMPT P43490 3/20 0.33
F10 P00742 2/20 0.32
PRSS1 P07477 1/20 0.32
PI4KA P42356 1/20 0.32
PI4KB Q9UBF8 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
MLYCD O95822 1/20 0.32
CYP17A1 P05093 1/20 0.32
CYP3A4 P08684 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6437619 0.92 PTPRC (0.42) DGAT2PTPRCMAPTF10KMT2A
SCHEMBL7378240 0.86 CA1 (0.42) CSNK2A2CSNK2BCSNK2A1CSNK2A3CA1
SCHEMBL6433064 0.82 S1PR1 (0.38) CYP3A4KMT2A
SCHEMBL6433230 0.81 ROCK2 (0.41) F10
SCHEMBL7363404 0.80 DGAT2 (0.41) DGAT2CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL6432917 0.79 TAS1R3 (0.37) DGAT2PRSS1CYP17A1CYP3A4CA1
SCHEMBL6434401 0.79 TAS1R3 (0.42) MAPTKMT2A
Hydrochloric Acid SCHEMBL7447049 0.79 CA1 (0.39) PTPRCMAPTPRSS1CA1CA2
SCHEMBL7375959 0.78 F2 (0.37) SMN1; SMN2F10KMT2A
SCHEMBL7371013 0.78 AGTR1 (0.32) PTPRCF10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 DGAT2 2226/4885CSNK2A2 1721/4885CSNK2B 1370/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 DGAT2 2226/4885CSNK2A2 1721/4885CSNK2B 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.